Volition in $28M Pact with Heska to Distribute Nu.Q® Vet Cancer Screening

 In exchange for granting Heska these exclusive worldwide rights to sell the Nu.Q® Vet Cancer Test, Volition will receive:

• a $10 million upfront payment on signing and

• up to $18 million based upon the achievement of near/mid-term milestones.

Volition's licensing agreement with Heska grants exclusive rights to commercialize the Nu.Q® Vet Cancer Screening Test for canine cancer screening and monitoring at the point of care. It also enables Heska to access a wider test menu for companion animals, including feline cancer.

In addition, Volition has granted Heska non-exclusive rights to sell the Nu.Q® Vet Cancer Screening Test in kit format for companion animals, through Heska's network of central reference laboratories.

Volition's Nu.Q® Vet Cancer Screening Test will operate on Heska's proprietary Element i+ Immunodiagnostic Analyzer, a point of care platform. By running the Nu.Q® Vet Cancer Screening Test on Heska's proprietary analyzers and tests, veterinarians will be able to screen millions of pets for some of the most common cancers to provide critical information to pet families accurately, cost effectively, and conveniently at the point of care. Heska's Nu.Q® Vet Cancer Screening Test targets one of the most critical challenges in pet healthcare.

https://finance.yahoo.com/news/volition-signs-exclusive-28-million-120000336.html